{"classes":[{"categories":[{"measurements":[{"comment":"Not evaluable due to insufficient number of events","groupId":"OG000","lowerLimit":"1","upperLimit":"NA","value":"3"},{"comment":"Not evaluable due to insufficient number of events","groupId":"OG001","lowerLimit":"1","upperLimit":"NA","value":"3"},{"comment":"Not evaluable due to insufficient number of events","groupId":"OG002","lowerLimit":"1","upperLimit":"NA","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"83"}],"units":"Participants"}],"description":"TTR, based on IMWG criteria per blinded IRC assessment, is the time between date of randomization to the date of first onset of PR or better response (iCR or sCR or CR or VGPR).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 20 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG000","title":"Arm A - Panobinostat (20 mg, TIW)"},{"description":"Participants received 20 mg panobinostat BIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG001","title":"Arm B - Panobinostat (20 mg, BIW)"},{"description":"Participants received 10 mg panobinostat TIW, 2 weeks on/1 week off in combination with subcutaneous bortezomib and oral dexamethasone.","id":"OG002","title":"Arm C - Panobinostat (10 mg, TIW)"}],"paramType":"MEDIAN","populationDescription":"Full analysis set (FAS): all participants to whom study treatment was assigned by randomization.","reportingStatus":"POSTED","timeFrame":"Up to 5.2 years","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"months"}